Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GMGamida Cell Ltd. logo

Gamida Cell Ltd. (GMDA)

NASDAQ Global Market · Currency in USD
$0.03 ▲ +0.00 (+0.00%)
At close: Jun 17, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.03
Open
$0.04
Day's Range
$0.03 – $0.04
52 Week Range
$0.03 – $0.04
Volume
19,054,623
Avg. Volume
21,709,470
Market Cap
$4.34M
Beta (5Y Monthly)
1.03
PE Ratio (TTM)
--
EPS (TTM)
-$0.42
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Gamida Cell Ltd.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
143
CEO
Abigail L. Jenkins

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia.

Earnings

DateEst.Actual
May 20, 2024–$0.13
Mar 27, 2024-$0.13-$0.04Beat
Nov 14, 2023-$0.15-$0.01Beat
Aug 14, 2023-$0.18-$0.31Miss
May 15, 2023-$0.27-$0.27Beat
Mar 27, 2023-$0.24-$0.29Miss

Analyst view

Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on GMDA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.